NCT07741045
Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Start date changed from estimate of Aug 3, 2026 to Nov 5, 2026
- Eligibility criteria expanded, about 31 words
- Primary endpoints: details revised at 1 of 1 entry
- Site details revised at 21 of 21 sites
- Notable Eligibility criteria expanded, about 3 wordsv2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change from baseline in the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score in off-anti-PD medication state at Week 26. "Off-anti-PD medication state" is defined as: ≥12 hours after the last dose of anti-PD medication
Timeframe: After 26 weeks of treatment
Arms and interventions
TJ0113 200mgExperimental
Subjects will receive 100 mg of TJ0113 capsules for 52 consecutive weeks
TJ0113 400mgExperimental
Subjects will receive 200 mg of TJ0113 capsules for 52 consecutive weeks
PlaceboPlacebo comparator
Subjects will receive 200mg or 400 mg of placebo for 26 consecutive weeks,and receive 200 mg or 400 mg of TJ0113 capsules for 26 consecutive weeks
Drugs: TJ0113 200mg, TJ0113 400mg, Placebo
Sites
21 sites in 1 country